Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study
Year: 2025
Type: article
Language: en
Topic: Hepatocellular Carcinoma Treatment and Prognosis
Authors and affiliations:
raw_author_name: Sangdao Boonkaya
raw_affiliation_strings: Department of Internal Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand
Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
raw_author_name: Chidkamon Pattarawongpaiboon
raw_affiliation_strings: Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
raw_author_name: Panarat Thaimai
raw_affiliation_strings: Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
raw_author_name: Prooksa Ananchuensook
raw_affiliation_strings: Center of Excellence in Hepatic Fibrosis and Cirrhosis, Chulalongkorn University, Bangkok, Thailand
Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
raw_author_name: Supachaya Sriphoosanaphan
raw_affiliation_strings: Center of Excellence in Hepatic Fibrosis and Cirrhosis, Chulalongkorn University, Bangkok, Thailand
Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
raw_author_name: Suebpong Tanasanvimon
raw_affiliation_strings: Division of Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
raw_author_name: Nattaya Teeyapun
raw_affiliation_strings: Division of Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
raw_author_name: Nussara Pakvisal
raw_affiliation_strings: Division of Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
raw_author_name: Nipaporn Siripon
raw_affiliation_strings: Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
raw_author_name: Sombat Treeprasertsuk
raw_affiliation_strings: Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
raw_author_name: Piyawat Komolmit
raw_affiliation_strings: Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
raw_author_name: Kessarin Thanapirom
raw_affiliation_strings: Center of Excellence in Hepatic Fibrosis and Cirrhosis, Chulalongkorn University, Bangkok, Thailand
Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand